Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon

Version 1 : Received: 27 April 2022 / Approved: 28 April 2022 / Online: 28 April 2022 (03:28:50 CEST)

How to cite: Sgorlon-Oliveira, G.; Queiroz, J. A. D. S.; Gasparelo, N. W. F.; Roca, T. P.; Passos-Silva, A. M.; Teixeira, K. S.; Oliveira, A. A. D. S.; Souza, P. R. F. D.; Silva, E. D. S.; Silva, C. C. D.; Maia, A. C. S.; Azzi, C. F. G.; Batista, F. S.; Souza, V. R. D.; Oliveira, F. M.; Salcedo, J. M. V.; Pereira, S. D. S.; Naveca, F. G.; Rampazzo, R. D. C. P.; Morello, L. G.; Marchini, F. K.; Vieira, D. The SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon. Preprints 2022, 2022040266. https://doi.org/10.20944/preprints202204.0266.v1 Sgorlon-Oliveira, G.; Queiroz, J. A. D. S.; Gasparelo, N. W. F.; Roca, T. P.; Passos-Silva, A. M.; Teixeira, K. S.; Oliveira, A. A. D. S.; Souza, P. R. F. D.; Silva, E. D. S.; Silva, C. C. D.; Maia, A. C. S.; Azzi, C. F. G.; Batista, F. S.; Souza, V. R. D.; Oliveira, F. M.; Salcedo, J. M. V.; Pereira, S. D. S.; Naveca, F. G.; Rampazzo, R. D. C. P.; Morello, L. G.; Marchini, F. K.; Vieira, D. The SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon. Preprints 2022, 2022040266. https://doi.org/10.20944/preprints202204.0266.v1

Abstract

Genomic surveillance represents an important strategy for understanding evolutionary mechanisms, transmission profile, and infectivity of different SARS-CoV-2 variants. We assessed the epidemiological profile of 366 individuals who tested positive for SARS-CoV-2 from 29 municipalities in Rondônia between December 2021 to March 2022. Samples were collected, RNA was ex-tracted and screened using RT-qPCR for Alpha, Beta, Gamma, Delta and Omicron VOCs and viral quantification was performed. Sequences were analyzed for phylogeny, mutations and lineages. Of the samples analyzed, 93.71% were positive for the Omicron variant and 6.28% were positive for the Delta variant. The symptoms observed were cough, sore throat, and fever, with a mean duration of 5 days; no hospitalizations or deaths were reported. We noted that among the positive individuals, 51% had been immunized with two doses, 22% received three doses, 13% received one dose, and 13% were not immunized. Just 242 samples were amenable to analysis for alignment and phylogenetic characterization; corresponding to variants BA.1 and BA.1.1; a total of 120 mutations were identified, 36% of which were found in the S gene. In conclusion, there was a high frequency of mutations in the SARS-CoV-2 genome, but no record of clinical severity, demonstrating the positive effect of vaccination.

Keywords

SARS CoV-2; Variant of Concern; Omicron; mutation; genomic surveillance

Subject

Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.